18 May 2020 ORYZON announces enrollment of first patient in ESCAPE: a Phase II clinical trial with vafidemstat in severely ill COVID-19 patients
24 April 2020 ORYZON to initiate ESCAPE: a Phase II clinical trial to test efficacy of vafidemstat in severely ill COVID-19 patients
3 April 2020 ORYZON presents efficacy data from its two vafidemstat clinical trials in Alzheimer’s disease at the virtual AAT-AD/PD 2020 Conference
24 February 2020 ORYZON Reports Financial Results and Corporate Update for the 4thQuarter and Year Ended December 31, 2019